938462-32-9

Usage

Uses

Used in Pharmaceutical Industry:
(2S)-2-AMINO-3-(2-METHOXYPHENYL)PROPAN-1-OL is used as a chiral building block for the synthesis of various pharmaceuticals. Its unique structure allows for the creation of enantiomerically pure compounds, which is crucial for the development of effective and safe medications.
Used in Agrochemical Industry:
In the agrochemical industry, (2S)-2-AMINO-3-(2-METHOXYPHENYL)PROPAN-1-OL serves as a chiral building block for the synthesis of enantiomerically pure agrochemicals. This ensures the development of more targeted and environmentally friendly products.
Used in Organic Synthesis:
(2S)-2-AMINO-3-(2-METHOXYPHENYL)PROPAN-1-OL is used as a versatile chiral building block in organic synthesis, enabling the creation of a wide range of complex organic molecules with potential applications in various industries.

Upstream product

• 1255037-13-8 (R)-3-(2-methoxyphenyl)-2-nitropropan-1-ol 
• 170642-31-6 (2R)-2-amino-3-(2-methoxyphenyl)propanoic acid 

Relevant academic research and scientific papers

Two Distinct Mechanisms of Inhibition of LpxA Acyltransferase Essential for Lipopolysaccharide Biosynthesis

The lipopolysaccharide biosynthesis pathway is considered an attractive drug target against the rising threat of multi-drug-resistant Gram-negative bacteria. Here, we report two novel small-molecule inhibitors (compounds 1 and 2) of the acyltransferase LpxA, the first enzyme in the lipopolysaccharide biosynthesis pathway. We show genetically that the antibacterial activities of the compounds against efflux-deficient Escherichia coli are mediated by LpxA inhibition. Consistently, the compounds inhibited the LpxA enzymatic reaction in vitro. Intriguingly, using biochemical, biophysical, and structural characterization, we reveal two distinct mechanisms of LpxA inhibition; compound 1 is a substrate-competitive inhibitor targeting apo LpxA, and compound 2 is an uncompetitive inhibitor targeting the LpxA/product complex. Compound 2 exhibited more favorable biological and physicochemical properties than compound 1 and was optimized using structural information to achieve improved antibacterial activity against wild-type E. coli. These results show that LpxA is a promising antibacterial target and imply the advantages of targeting enzyme/product complexes in drug discovery.

Biocatalytic enantioselective approach to 3-aryl-2-nitropropanols: Synthesis of enantioenriched (R)-5-methoxy-3-aminochroman, a key precursor to the antidepressant drug Robalzotan

The results of our studies on the biocatalytic enantioselective synthesis of different 3-aryl-2-nitropropanols are presented. These compounds could be obtained in moderate to good ee both bybaker's yeast mediated reduction of (E)-2-nitro-3-arylprop-2-en-1-ol precursors and by lipase kinetic resolution of racemic 3-aryl-2-nitropropanols. The synthesis of enantioenriched (R)-5-methoxy-3-aminochroman is also achieved. This important moietyispresent in different molecules active toward the central nervous system and is also the precursor for the synthesis of Robalzotan (NAD299), a potent 5-HT1A antagonist.